Lobular neoplasia

Surgical Oncology Clinics of North America

Volumn 23, Issue 3, 2014, Pages 487-503

  King, Tari A ^a   Reis Filho, Jorge S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Atypical lobular hyperplasia; Breast cancer risk; Chemoprevention; E cadherin; Lobular carcinoma in situ; Lobular neoplasia

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN P53; RALOXIFENE; TAMOXIFEN; UVOMORULIN; CADHERIN;

ATYPICAL LOBULAR HYPERPLASIA; BREAST CANCER; BREAST CARCINOMA; BREAST HYPERPLASIA; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CORE NEEDLE BIOPSY; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; GENE DELETION; GENE LOSS; HER2 GENE; HUMAN; INTRADUCTAL CARCINOMA; LOBULAR CARCINOMA IN SITU; MASTECTOMY; METHYLATION; NEEDLE BIOPSY; NONHUMAN; PATHOLOGICAL ANATOMY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; TUMOR GENE; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; FEMALE; GENETICS; HYPERPLASIA; PATHOLOGY; PRECANCEROUS CONDITIONS; RISK;

BREAST NEOPLASMS; CADHERINS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; FEMALE; HUMANS; HYPERPLASIA; PRECANCEROUS CONDITIONS; RISK;

EID: 84901650644     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.03.002     Document Type: Review

References (80)

1. WHO classification of tumours of the breast 2012, IARC Press, Lyon (France). S.R. Lakhani, I.O. Ellis, S.J. Schnitt (Eds.).
2. Ewing J. Neoplastic diseases: a textbook on tumors 1919, WB Saunders, Philadelphia.
3. Foote F.W., Stewart F.W. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 1941, 17(4):491-496. 3.
4. Haagensen C.D., Lane N., Lattes R., et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978, 42(2):737-769.
5. Rosen P.P., Kosloff C., Lieberman P.H., et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978, 2(3):225-251.
6. Page D.L., Vander Zwaag R., Rogers L.W., et al. Relation between component parts of fibrocystic disease complex and breast cancer. JNatl Cancer Inst 1978, 61(4):1055-1063.
7. Andrade V.P., Ostrovnaya I., Seshan V.E., et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res 2012, 14(4):R103.
8. Aulmann S., Penzel R., Longerich T., et al. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat 2008, 107(3):331-335.
9. Lopez-Garcia M.A., Geyer F.C., Lacroix-Triki M., et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010, 57(2):171-192.
10. Page D.L., Schuyler P.A., Dupont W.D., et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003, 361(9352):125-129.
11. Vos C.B., Cleton-Jansen A.M., Berx G., et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997, 76(9):1131-1133.
12. Reis-Filho J.S., Pinder S.E. Non-operative breast pathology: lobular neoplasia. JClin Pathol 2007, 60(12):1321-1327.
13. Sneige N., Wang J., Baker B.A., et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002, 15(10):1044-1050.
14. Page D.L. Atypical hyperplasia, narrowly and broadly defined. Hum Pathol 1991, 22(7):631-632.
15. Page D.L., Dupont W.D., Rogers L.W., et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985, 55(11):2698-2708.
16. Eusebi V., Magalhaes F., Azzopardi J.G. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992, 23(6):655-662.
17. Chen Y.Y., Hwang E.S., Roy R., et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol 2009, 33(11):1683-1694.
18. Bratthauer G.L., Saenger J.S., Strauss B.L. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology 2005, 47(6):611-616.
19. Boldt V., Stacher E., Halbwedl I., et al. Positioning of necrotic lobular intraepithelial neoplasias (LIN, grade 3) within the sequence of breast carcinoma progression. Genes Chromosomes Cancer 2010, 49(5):463-470.
20. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378(9805):1812-1823.
21. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
22. Geyer F.C., Lacroix-Triki M., Savage K., et al. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011, 24(2):209-231.
23. Dabbs D.J., Bhargava R., Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol 2007, 31(3):427-437.
24. Morrogh M., Andrade V.P., Giri D., et al. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat 2012, 132(2):641-652.
25. Jacobs T.W., Pliss N., Kouria G., et al. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001, 25(2):229-236.
26. Dabbs D.J., Schnitt S.J., Geyer F.C., et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol 2013, 37(7):e1-e11.
27. Rakha E.A., Patel A., Powe D.G., et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2010, 34(10):1472-1479.
28. Da Silva L., Parry S., Reid L., et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008, 32(5):773-783.
29. Derksen P.W., Liu X., Saridin F., et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10(5):437-449.
30. Aigner K., Dampier B., Descovich L., et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26(49):6979-6988.
31. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392(6674):402-405.
32. Schrader K.A., Masciari S., Boyd N., et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. JMed Genet 2011, 48(1):64-68.
33. Lu Y.J., Osin P., Lakhani S.R., et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998, 58(20):4721-4727.
34. Hwang E.S., Nyante S.J., Yi Chen Y., et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004, 100(12):2562-2572.
35. Reis-Filho J.S., Simpson P.T., Jones C., et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. JPathol 2005, 207(1):1-13.
36. Simpson P.T., Reis-Filho J.S., Lambros M.B., et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. JPathol 2008, 215(3):231-244.
37. Wheeler J.E., Enterline H.T., Roseman J.M., et al. Lobular carcinoma in situ of the breast. Long-term followup. Cancer 1974, 34(3):554-563.
38. Hussain M., Cunnick G.H. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast-a review. Eur J Surg Oncol 2011, 37(4):279-289.
39. Li C.I., Anderson B.O., Daling J.R., et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 2002, 75(3):259-268.
40. Li C.I., Malone K.E., Saltzman B.S., et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006, 106(10):2104-2112.
41. Urban J.A. Bilaterality of cancer of the breast. Biopsy of the opposite breast. Cancer 1967, 20(11):1867-1870.
42. Rosen P.P., Senie R., Schottenfeld D., et al. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 1979, 189(3):377-382.
43. Liberman L., Holland A.E., Marjan D., et al. Underestimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol 2007, 188(3):684-690.
44. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. NEngl J Med 1985, 312(3):146-151.
45. Chuba P.J., Hamre M.R., Yap J., et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. JClin Oncol 2005, 23(24):5534-5541.
46. Bodian C.A., Perzin K.H., Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996, 78(5):1024-1034.
47. Fisher E.R., Land S.R., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 2004, 100(2):238-244.
48. Andersen J.A. Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer 1977, 39(6):2597-2602.
49. Collins L.C., Baer H.J., Tamimi R.M., et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer 2007, 109(2):180-187.
50. Li C.I., Anderson B.O., Porter P., et al. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000, 88(11):2561-2569.
51. Oppong B.A., King T.A. Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park) 2011, 25(11):1051-1056. 8.
52. Abner A.L., Connolly J.L., Recht A., et al. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer 2000, 88(5):1072-1077.
53. Ben-David M.A., Kleer C.G., Paramagul C., et al. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis. Cancer 2006, 106(1):28-34.
54. Ciocca R.M., Li T., Freedman G.M., et al. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol 2008, 15(8):2263-2271.
55. Downs-Kelly E., Bell D., Perkins G.H., et al. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med 2011, 135(6):737-743.
56. Walker R.A., Hanby A., Pinder S.E., National Coordinating Committee for Breast Pathology Research Subgroup, et al. Current issues in diagnostic breast pathology. JClin Pathol 2012, 65(9):771-785.
57. National Comprehensive Cancer Network. Available at:. Accessed September 20, 2013. http://www.nccn.org.
58. Georgian-Smith D., Lawton T.J. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol 2001, 176(5):1255-1259.
59. Kilbride K.E., Newman L.A. Lobular carcinoma in situ: clinical management. Diseases of the breast 2010, 341-348. Lippincott Williams & Wilkins, Philadelphia. 4th edition. J.R. Harris, M.E. Lippman, M. Morrow (Eds.).
60. Lavoue V., Graesslin O., Classe J.M., et al. Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow-up surgical excision. Breast 2007, 16(5):533-539.
61. Mahoney M.C., Robinson-Smith T.M., Shaughnessy E.A. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up. AJR Am J Roentgenol 2006, 187(4):949-954.
62. Pacelli A., Rhodes D.J., Amrami K.K., et al. Outcome of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed by core needle biopsy: clinical and surgical follow-up of 30 cases. Am J Clin Pathol 2001, 116(4):591-592.
63. Murray M.P., Luedtke C., Liberman L., et al. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer 2013, 119(5):1073-1079.
64. Rendi M.H., Dintzis S.M., Lehman C.D., et al. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol 2012, 19(3):914-921.
65. Shah-Khan M.G., Geiger X.J., Reynolds C., et al. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol 2012, 19(10):3131-3138.
66. Subhawong A.P., Subhawong T.K., Khouri N., et al. Incidental minimal atypical lobular hyperplasia on core needle biopsy: correlation with findings on follow-up excision. Am J Surg Pathol 2010, 34(6):822-828.
67. King TA, Reis-Filho JS. Lobular carcinoma in situ: biology and management. In: Harris JR, Lippman ME, Morrow M, etal, editors. Diseases of the breast. 5th edition. Philadelphia: Lippincott Williams & Wilkins; in press.,
68. Bevers T.B., Anderson B.O., Bonaccio E., et al. Breast cancer screening and diagnosis. JNatl Compr Canc Netw 2006, 4(5):480-508.
69. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
70. King T.A., Muhsen S., Patil S., et al. Is there a role for routine screening MRI in women with LCIS?. Breast Cancer Res Treat 2013, 142(2):445-453.
71. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 1998, 90(18):1371-1388.
72. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(23):2727-2741.
73. Ropka M.E., Keim J., Philbrick J.T. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. JClin Oncol 2010, 28(18):3090-3095.
74. Chlebowski R.T., Collyar D.E., Somerfield M.R., et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. JClin Oncol 1999, 17(6):1939-1955.
75. Chlebowski R.T., Col N., Winer E.P., et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. JClin Oncol 2002, 20(15):3328-3343.
76. Visvanathan K., Chlebowski R.T., Hurley P., et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. JClin Oncol 2009, 27(19):3235-3258.
77. Visvanathan K., Hurley P., Bantug E., et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. JClin Oncol 2013, 31(23):2942-2962.
78. Goss P.E., Ingle J.N., Ales-Martinez J.E., et al. Exemestane for breast-cancer prevention in postmenopausal women. NEngl J Med 2011, 364(25):2381-2391.
79. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. NEngl J Med 1999, 340(2):77-84.
80. Geiger A.M., Yu O., Herrinton L.J., et al. Apopulation-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med 2005, 165(5):516-520.